TEVA-DICLOFENAC EC TABLET (ENTERIC-COATED)

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

DICLOFENAC SODIUM

Διαθέσιμο από:

TEVA CANADA LIMITED

Φαρμακολογική κατηγορία (ATC):

M01AB05

INN (Διεθνής Όνομα):

DICLOFENAC

Δοσολογία:

50MG

Φαρμακοτεχνική μορφή:

TABLET (ENTERIC-COATED)

Σύνθεση:

DICLOFENAC SODIUM 50MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100/500

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0114417002; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2010-10-08

Αρχείο Π.Χ.Π.

_TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR Page 1 of 54 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVA-DICLOFENAC EC
Pr
TEVA-DICLOFENAC SR
Diclofenac Sodium Enteric Coated Tablets
Diclofenac Sodium Slow-Release Tablets
Enteric Coated Tablets, 25 mg, 50 mg, Oral
Slow-release Tablets, 75 mg and 100 mg, Oral
Teva Standard
Non-Steroidal Anti-Inflammatory Drug
(NSAID)
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
October 08, 2010
Date of Revision:
December 20, 2022
Submission Control Number: 266861
_TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR Page 2 of 54 _
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX- Risk in Pregnancy
12/2022
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests,
_Pregnancy_
12/2022
7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions _
12/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
12/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...............................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I:
HEALTH PROFESSIONAL
INFORMATION....................................................................
4
1
INDICATIONS.................................................................................................................
4
1.1
Pediatrics
............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS....................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................... 6
4
DOSAGE AN